The company’s stock plunged by $27.14 per share on July 14, 2026, settling at $363.60 following a preliminary second-quarter report. Management attributed the downturn to an unfavorable shift in the firm's payer mix, a disclosure that directly prompted the legal scrutiny. Investors who sustained losses are now being solicited to contact Danielle Peyton at Pomerantz LLP to discuss potential class action participation.

Pomerantz LLP, a firm with a long-standing history in securities litigation, is evaluating whether the company’s disclosures misled shareholders regarding its financial health. While the investigation remains in its early stages, the firm is seeking to determine if the reported revenue shortfall constitutes a breach of fiduciary duty or unlawful business practices.